Esterified estrogens/methyltestosterone
From Wikipedia, the free encyclopedia
(Redirected from Estratest)
Pharmaceutical combination
 | This article needs more citations. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Esterified estrogens/methyltestosterone" – news · newspapers · books · scholar · JSTOR (November 2017) (Learn how and when to remove this message) |
Pharmaceutical compound
 | |
 | |
| Combination of | |
|---|---|
| Esterified estrogens | Estrogen |
| Methyltestosterone | Androgen; Anabolic steroid |
| Clinical data | |
| Trade names | Covaryx, Essian, Estratest, Menogen, Syntest |
| Other names | EEs/MT |
| Routes of administration | By mouth |
| Drug class | Estrogen; Androgen |
| ATC code | |
| Identifiers | |
| CAS Number | |
Esterified estrogens/methyltestosterone (EEs/MT), sold under brand names such as Covaryx, Eemt, Essian, Estratest, Menogen, and Syntest, is a hormonal preparation that combines esterified estrogens (EEs) with methyltestosterone (MT) in one tablet and is used in menopausal hormone therapy.[1]
Medical uses
[edit source]EEs/MT is used to treat menopausal women who suffer from hot flashes, but do not get relief from estrogen-only therapy.
Available forms
[edit source]EEs/MT is sold in tablet form, with either 1.25 mg EEs/2.5 mg MT or 0.625 mg EEs/1.25 mg MT available.
Pharmacology
[edit source]The product is a combination of esterified estrogens, an estrogen, and low-dose methyltestosterone, an androgen/anabolic steroid, in a single tablet.
Side effects
[edit source]EEs/MT treatment resulted in a relatively small number of serious adverse events.[2]
History
[edit source]EEs/MT was first marketed in the United States in 1965 by Reid-Provident Laboratories, which as 100% of Reid-Rowell, Inc. stock was acquired by the Belgian pharmaceutical company Solvay in 1986. There has been some controversy surrounding the drug in recent years as to its status with the U.S. Food and Drug Administration.
Solvay sponsored a clinical trial of EEs/MT in the United States to determine whether the product is superior to treatment with esterified estrogens tablets.
EEs/MT was supplied by Solvay. In March 2009 Solvay announced that, based on a variety of business factors, it would discontinue supplying Estratest and Estratest HS tablets, and would stop accepting orders for the product on March 31, 2009.
See also
[edit source]References
[edit source]- ↑ "Esterified Estrogens And Methyltestosterone (Oral Route)". Mayo Clinic. Mayo Foundation for Medical Education and Research.
- ↑ Phillips EH, Ryan S, Ferrari R, Green C (December 2003). "Estratest and Estratest HS (esterified estrogens and methyltestosterone) therapy: a summary of safety surveillance data, January 1989 to August 2002". Clinical Therapeutics. 25 (12): 3027–3043. doi:10.1016/s0149-2918(03)90090-7. PMID 14749144.
External links
[edit source]
| |||||||||||||||||||||||||||||||||||||
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Articles needing additional references from November 2017
- All articles needing additional references
- Short description is different from Wikidata
- Infobox drug articles with non-default infobox title
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals